Physician profile
Gary A Wruble
NPI 1215939897
$2,293.10
in general payments reported to CMS, 2019-2025
24 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $106 · 2021: $84.97 · 2022: $385 · 2023: $190 · 2024: $302 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $824.35 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $560.65 | 2019-2024 | Xifaxan, Plenvu, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $159.46 | 2019 | |
| Janssen Biotech, INC. | $133.07 | 2019-2023 | Simponi, Simponi Aria, Stelara |
| Gilead Sciences, INC. | $73.22 | 2019-2023 | |
| Genzyme Corporation | $69.97 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $67.89 | 2022-2023 | |
| Pfizer INC. | $67.32 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $62.82 | 2019-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $35.82 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $34.35 | 2024-2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $33.36 | 2022-2024 | Dificid |
| Qol Medical, LLC | $20.14 | 2025 | Sucraid |
| Shire North American Group INC | $17.46 | 2019 | |
| Celltrion USA INC. | $16.06 | 2025 | Vegzelma |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $15.18 | 2024 | Button |
| Celgene Corporation | $14.33 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.81 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.56 | 2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $13.55 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.89 | 2019 | |
| Ucb, INC. | $11.89 | 2019 | |
| Daiichi Sankyo INC. | $11.05 | 2019 | |
| Ferring Pharmaceuticals INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Wruble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.